Oestrogen receptors, nodes and stage as predictors of post-recurrence survival in 457 breast cancer patients

Abstract

(Samaan et al., 1981). These subset inconsistencies and differences in RFS observed in early follow-up tend to disappear in the long-term (Howat et al., 1985;Raemaekers et al., 1985;Saez et al., 1983). This unclear role of ER in predicting RFS impacts on the question of whether overall survival is more favourable in ER+ than ER-tumours because of longer RFS, or longer post-recurrence survival (PRS), or both.The association of ER with PRS has been relatively less scrutinized. In a study based on 137 patients with recurrence, Howell et al. (1984) reported that ER+ patients showed a significantly longer survival after relapse than ER-patients. However, this effect was related to response to endocrine therapy. PRS was the same in ER+ nonresponders (n=19) as ER-nonresponders (n= 18) but both groups had significantly worse PRS than ER + responders (n = 24). Howat et al. (1985) in a relatively small study (n=51) found that PRS was better in ER+ patients and suggested this to be predominantly a result of better response to endocrine therapy given for recurrence.We also found a significant association of higher ER concentration and increased PRS among a subset (n=59) which had received endocrine therapy (Godolphin et al., 1981). The patients of that previous study have now been followed up to ten years. Additional patients whose primary tumours were diagnosed and analysed for ER

Gene expression signatures of morphologically normal breast tissue identify basal-like tumors

“…Notably, ER status, which is often the most important classifier of tumors, both clinically and at the molecular level [4,10], did not associate with any clusters observed in normal stroma or epithelium, nor were we able to identify any predictors for this clinical category. Identical approaches of class distinction, class prediction, and class discovery failed to identify biologically relevant or statistically significant predictors, or clusters associated with any of the other clinical characteristics tested (Additional files 2 and 3).…”

Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data

“…[3][4][5] Although the relation between breast cancer molecular subtype and survival has been studied in other jurisdictions, including British Columbia, 6,7 limited information is available for Ontario. The goal of this study was to determine how breast cancer molecular subtype affects survival among Ontario women and how survival for each subtype varies by selected demographic and tumour-based characteristics.…”

NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis

“…Although ER-positive breast cancers respond to hormonal therapy, the prognosis for ER-negative breast cancers is poorer because of the lack of target-directed therapies and a more clinically aggressive biology (4,(8)(9)(10)(11). Treatment of human breast cancers, containing an amplified ErbB2 gene, with a humanized monoclonal antibody to the extracellular domain of this receptor (trastuzumab, marketed as herceptin) produces remissions in 11-15% of patients with metastatic breast cancer failing standard chemotherapy (12)(13)(14).…”